Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Kao, Chester, Daniel J. George, and Tian Zhang. “An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).” Oncologist 26, no. 3 (March 2021): e508–11. https://doi.org/10.1002/onco.13617.

PMID
33251710
Full Text

Brown, Landon C., Matthew D. Tucker, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew K. Labriola, et al. “LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.” J Immunother Cancer 9, no. 3 (March 2021). https://doi.org/10.1136/jitc-2020-001792.

PMID
33653800
Full Text

Tagawa, Scott T., Krishnan Ramaswamy, Ahong Huang, Jack Mardekian, Neil M. Schultz, Li Wang, Rickard Sandin, Stanislav Lechpammer, and Daniel J. George. “Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.” Prostate Cancer Prostatic Dis, February 21, 2021. https://doi.org/10.1038/s41391-021-00318-3.

PMID
33612825
Full Text

Pal, Sumanta K., Catherine Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y. C. Heng, Brian Shuch, et al. “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.” Lancet 397, no. 10275 (February 20, 2021): 695–703. https://doi.org/10.1016/S0140-6736(21)00152-5.

PMID
33592176
Full Text

Zhang, Tian, Anika Agarwal, R Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.” Biomark Res 9, no. 1 (February 18, 2021): 14. https://doi.org/10.1186/s40364-021-00267-y.

PMID
33602330
Full Text

Patel, Anup, Alain Ravaud, Robert J. Motzer, Allan J. Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, and Daniel J. George. “Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.” Future Oncol 17, no. 4 (February 2021): 403–9. https://doi.org/10.2217/fon-2020-0652.

PMID
33028084
Full Text

Shah, Anand, Thomas J. Polascik, Daniel J. George, John Anderson, Terry Hyslop, Alicia M. Ellis, Andrew J. Armstrong, et al. “Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.” In J Gen Intern Med, 36:92–99, 2021. https://doi.org/10.1007/s11606-020-06124-2.

PMID
32875501
Full Text

Chen, Ronald C., Toni K. Choueiri, Marion Feuilly, Jie Meng, Johanna Lister, Florence Marteau, Aaron D. Falchook, Michael J. Morris, Daniel J. George, and Darren R. Feldman. “Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).” Cancer 126, no. 24 (December 15, 2020): 5311–18. https://doi.org/10.1002/cncr.33169.

PMID
33022096
Full Text

Shore, Neal, Celestia S. Higano, Daniel J. George, Cora N. Sternberg, Fred Saad, Bertrand Tombal, Kurt Miller, et al. “Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis 23, no. 4 (December 2020): 680–88. https://doi.org/10.1038/s41391-020-0236-0.

PMID
32404868
Full Text

Brown, Landon C., Jason Zhu, Matthew K. Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, et al. “PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.” Clin Genitourin Cancer 18, no. 6 (December 2020): 509–13. https://doi.org/10.1016/j.clgc.2020.03.020.

PMID
32482566
Full Text

Pages